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Abstract:  
 
The COMBINE (Combined Pharmacotherapies and Behavioral Intervention) clinical trial 
recently evaluated the efficacy of medications, behavioral therapies, and their combinations for 
the outpatient treatment of alcohol dependence. The costs and cost-effectiveness of these 
combinations are unknown and of interest to clinicians and policy makers. 
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Cost and Cost-effectiveness of the COMBINE Study
in Alcohol-Dependent Patients
Gary A. Zarkin, PhD; Jeremy W. Bray, PhD; Arnie Aldridge, MS; Debanjali Mitra, MA; Michael J. Mills, MA;
David J. Couper, PhD; Ron A. Cisler, PhD; for the COMBINE Cost-Effectiveness Research Group
Context: The COMBINE (Combined Pharmacothera-
pies and Behavioral Intervention) clinical trial recently
evaluated the efficacy of medications, behavioral thera-
pies, and their combinations for the outpatient treat-
ment of alcohol dependence. The costs and cost-
effectiveness of these combinations are unknown and of
interest to clinicians and policy makers.
Objective: To evaluate the costs and cost-effectiveness
of the COMBINE Study interventions after 16 weeks of
treatment.
Design: A prospective cost and cost-effectiveness study
of a randomized controlled clinical trial.
Setting: Eleven US clinical sites.
Participants: One thousand three hundred eighty-
three patients having a diagnosis of primary alcohol de-
pendence.
Interventions: The study included 9 treatment
groups; 4 groups received medical management for 16
weeks with naltrexone, 100 mg/d, acamprosate, 3 g/d,
or both, and/or placebo; 4 groups received the same
therapy as mentioned earlier with combined behavioral
intervention; and 1 group received combined behav-
ioral intervention only.
Main Outcomes Measures: Incremental cost per per-
centage point increase in percentage of days abstinent,
incremental cost per patient of avoiding heavy drink-
ing, and incremental cost per patient of achieving a good
clinical outcome.
Results: On the basis of the mean values of cost and ef-
fectiveness, 3 interventions are cost-effective options rela-
tive to the other interventions for all 3 outcomes: medi-
cal management (MM) with placebo ($409 per patient),
MM plus naltrexone therapy ($671 per patient), and MM
plus combined naltrexone and acamprosate therapy
($1003 per patient).
Conclusions: To our knowledge, this is only the second
prospective cost-effectiveness study with a randomized con-
trolled clinical trial design that has been performed for the
treatment of alcohol dependence. Focusing only on effec-
tiveness, MM-naltrexone-acamprosate therapy is not sig-
nificantly better than MM-naltrexone therapy. However,
considering cost and cost-effectiveness, MM-naltrexone-
acamprosate therapy may be a better choice, depending on
whether the cost of the incremental increase in effective-
ness is justified by the decision maker.
Trial Registration: clinicaltrials.gov Identifier:
NCT00006206
Arch Gen Psychiatry. 2008;65(10):1214-1221
A LCOHOL USE IS THE THIRDleading preventable causeof death,1 and alcoholabuse and dependence im-pose substantial costs on
society. In 1998, the estimated societal cost
of alcohol abuse in the United States was
$184 billion.2 The sizable economic and
societal costs of alcohol abuse and depen-
dence have prompted considerable inter-
est in developing interventions to amelio-
rate these costs and to improve patient
functioning. Several behavioral interven-
tions3 and 2 pharmacotherapies—
naltrexone and acamprosate4,5—have been
shown to be efficacious.
Based on evidence for both ap-
proaches, the COMBINE (Combined Phar-
macotherapies and Behavioral Interven-
tions) Study was designed to examine the
effects of combining behavioral therapy
and pharmacotherapy in the treatment of
alcohol dependence.6-9 COMBINE, a mul-
ticenter, randomized, controlled clinical
trial sponsored by the National Institute
on Alcohol Abuse and Alcoholism, was the
first study to investigate whether combi-
nations of pharmacotherapies (naltrex-
one and acamprosate) with medical man-
agement (MM) and a combined behavioral
intervention (CBI) are superior to mono-
therapy in treating alcohol dependence. A
total of 1383 subjects across 11 sites were
randomized into 9 treatment groups be-
tween January 2001 and the end of treat-
ment in January 2004. Eight of the treat-
ment groups formed a 222 factorial
design. All participants in these groups re-
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ceived MM and were randomized to receive acampro-
sate or matching placebo plus naltrexone or matching pla-
cebo plus either CBI or no additional behavioral therapy.
The ninth treatment group received CBI only (no MM
or medication). The prespecified primary analyses in-
volved analysis of variance–type tests of main effects and
interactions in the 222 factorial part of the study.
Pairwise comparisons between treatment groups were not
prespecified analyses and were not reported in the main
findings article by Anton et al.10
Results for the primary clinical outcomes from the
COMBINE Study are available in Anton et al.10 In brief,
in the 16-week treatment period, patients receiving MM-
naltrexone therapy, CBI, or both had better drinking out-
comes than those receiving MM alone. The combina-
tion of naltrexone-CBI therapy showed no incremental
benefit over CBI or naltrexone therapy alone. Acampro-
sate therapy showed no evidence of efficacy with or with-
out CBI or naltrexone.
Because health care resources are limited, understand-
ing the cost and cost-effectiveness of the COMBINE in-
terventions is important to enable efficient allocation of
these resources. In this article, we evaluate the cost and
cost-effectiveness of the COMBINE Study after 16 weeks
of treatment. The only other randomized, controlled, clini-
cal trial–designed cost-effectiveness study11 did not evalu-
ate combinations of pharmaceutical and behavioral in-
terventions, as in our study.
METHODS
RECRUITMENT AND RANDOMIZATION
Participants were recruited via advertisement and from clini-
cal referrals. Each participant signed an informed consent ap-
proved by the institutional review board of each site, and each
site was issued a certificate of confidentiality by the National
Institute on Alcohol Abuse and Alcoholism. Eligibility criteria
included the following: (1) alcohol dependence as determined
by DSM-IV12 criteria; (2) 4 to 21 days of abstinence; and (3)
more than 14 drinks per week for women or 21 drinks per week
for men, with at least 2 heavy-drinking days, defined as 4 drinks
per day for women and 5 drinks per day for men, during a con-
secutive 30-day period within the 90 days before baseline evalu-
ation. Exclusion criteria included the following: (1) history of
other substance abuse excluding nicotine or cannabis accord-
ing to DSM-IV criteria in the last 90 days (6 months for opiate
abuse) or at urine drug screening, (2) psychiatric disorder re-
quiring medication, or (3) unstable medical condition (eg, se-
rum liver enzyme levels 3 times the upper limit of normal).
Participants’ median age was 44 years; 71% had at least 12 years
of education; and 42% were married. Racial/ethnic minorities
made up 23% of the sample. In the 30 days before randomiza-
tion, 2.3% of patients underwent medical detoxification and
7.7% received inpatient treatment. At baseline, mean percent-
age of days abstinent (PDA) was 25.0% and mean number of
drinks per drinking day was 12.5.
COST ESTIMATION
We used a microcosting approach to compute the costs of
COMBINE Study therapies from the perspective of the treat-
ment provider13 because this perspective is most relevant to de-
cision makers in best clinical practice. As described in Zarkin
et al,13 we identified COMBINE Study activities, laboratory pro-
cedures, and medications that would be needed to implement
the therapies in clinical practice, as opposed to those required
to implement a clinical trial research protocol, and estimated
the cost of each of these activities, updating unit cost esti-
mates to 2007 US dollars.
The cost of each COMBINE Study intervention was deter-
mined as the sum of space, labor, medication, and laboratory
costs for each treatment condition. We obtained pharmaceu-
tical costs for acamprosate and naltrexone from the Federal Sup-
ply Schedule, in which prices are negotiated by the Veterans
Administration and are publicly available. They are based on
the prices that manufacturers charge their most-favored non-
federal customers. The Federal Supply Schedule price of acam-
prosate is $0.64 per 333-mg tablet, and of naltrexone is $1.37
per 50-mg tablet. This translates to a daily cost of $5.76 for acam-
prosate and $2.74 for naltrexone when the naltrexone dose is
fully titrated.
To estimate labor costs, we obtained the actual clinician time
spent on MM and CBI from the data coordinating center data
management system. These data were collected prospectively
as part of the COMBINE Study. Salary data, including fringe
benefits, for all staff involved in COMBINE Study interven-
tions were obtained from the cost-effectiveness principal in-
vestigators at each site and adjusted to 2007 US dollars using
the Consumer Price Index. Time for all other activities (eg, staff
time to conduct a physical examination) and space use esti-
mates for all relevant COMBINE Study activities were ob-
tained from project coordinators at 9 of the 11 COMBINE Study
sites that participated in the cost study. The time spent on
COMBINE Study activities included time spent preparing for
each activity. Data on the number of times staff conducted each
activity were used to calculate a weighted hourly wage. For MM
and CBI sessions, labor cost is the product of the time spent
on each session and the median weighted hourly wage across
sites for personnel who conducted these sessions. For all other
activities, for which time was not tracked in the data manage-
ment system, the labor cost is the product of the median time
across sites spent on the activity and the median hourly wage
across sites. Space costs equal the median space costs per ac-
tivity across sites. See Zarkin et al13 for more details of the cost
methods.
To compute laboratory costs, we identified (with the help of
the COMBINE Study project coordinators and the cost-
effectiveness principal investigators) key laboratory tests from the
COMBINE Study protocol that are essential if these interven-
tions are implemented in clinical practice. We then associated each
test with a Current Procedural Terminology procedure code and
obtained baseline cost estimates for these procedures from the
2005Resource-BasedRelativeValueScale,14 which isusedbyMedi-
care to reimburse for services. These costs were adjusted to 2007
US dollars using the Consumer Price Index.
EFFECTIVENESS MEASURES
The 3 clinical outcomes assessed in our cost-effectiveness analy-
sis are the PDA, the proportion of patients who did not return
to heavy-drinking days (5 standard drinks per day for men
and 4 drinks per day for women), and the proportion of pa-
tients who maintained a good clinical outcome15 (abstinent or
moderate drinking without problems, with moderate drink-
ing defined as a maximum of 11 drinks per week for women
or 14 drinks per week for men, with no more than 2 days on
which women consumed more than 3 drinks or men con-
sumed 4 drinks; and problems defined as endorsing 3 items or
more on a standardized questionnaire16 that assessed social,
physical, and psychological consequences of drinking). All of
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these outcomes were measured through the end of the 16-
week treatment period. These outcomes mirror the primary out-
comes from Anton et al.10 As in that article,10 all outcomes were
adjusted for baseline PDA and clinical site.
COST-EFFECTIVENESS ANALYSIS
All interventions were ranked in increasing order of mean cost
(C) for each of the 3 effectiveness measures regardless of the
statistical significance of the cost or effectiveness estimates. In-
cremental cost-effectiveness ratios (ICERsij), defined as the dif-
ference in C divided by the difference in mean effectiveness (E),
(Cj−Ci)/(Ej−Ei), where intervention j is the next most costly
intervention compared with intervention i, were then com-
puted for each intervention relative to the next most costly op-
tion after eliminating treatment options that are economically
dominated by other treatments.17
An intervention is eliminated through strict dominance if there
is another intervention that is less expensive and more effective
than the eliminated intervention. An intervention is eliminated
through extended dominance if it has a greater ICER than a more
costly intervention.18 In that case, the cost of achieving a given
level of the outcome is lower if the dominated intervention is elimi-
nated. The nondominated interventions that remain make up the
cost-effectiveness frontier. The ICERs are computed and re-
ported for each intervention on the cost-effectiveness frontier with-
out regard to the statistical significance of the cost or effective-
ness differences between interventions.
Interventions that are not on the cost-effectiveness frontier
are not cost-effective alternatives and, therefore, are excluded
from further consideration. Choosing the optimal or most cost-
effective intervention from among those remaining on the cost-
effectiveness frontier depends on the perspective from which
the choice is made. Specifically, economic theory suggests that
the optimal intervention is the one with the greatest ICER that
is not more than the decision maker’s intrinsic valuation or will-
ingness to pay (WTP) for an additional unit of the outcome.18
To reflect sampling variability in our cost-effectiveness analy-
sis, we calculated cost-effectiveness acceptability curves as an
alternative to confidence intervals for ICERs.19,20 The cost-
effectiveness acceptability curves incorporate the inherent vari-
ability of the cost and effectiveness estimates (ie, their statis-
tical significance), and they show the probability that an
intervention is the most cost-effective as a function of the policy
maker’s intrinsic valuation or WTP for the clinical outcome.
We used nonparametric bootstrap methods to calculate cost-
effectiveness acceptability curves for all 9 intervention arms (see
also UKATT Research Team11 and Fenwick et al20).
SENSITIVITY ANALYSIS
In a trial such as the COMBINE Study in which medications are
a critical component of the intervention, pharmaceutical prices
may have a large effect on the cost results. Similarly, as observed
by Zarkin et al,13 labor costs make up the largest percentage of
activity costs. In our sensitivity analyses, we evaluated cost and
cost-effectiveness analyses with alternative pharmaceutical prices
and with alternative staff wages. Average wholesale price was used
as the upper limit for calculating pharmaceutical costs21 and has
also been used in previous cost and cost-effectiveness stud-
ies.22,23 The average wholesale price published in the Red Book is
in most cases the manufacturer’s suggested average wholesale price
and does not necessarily reflect the actual average wholesale price
charged by a wholesaler. The average wholesale price is some-
times referred to as the “sticker price” because it is often higher
than the price that large purchasers normally pay. The average
wholesale prices for acamprosate and naltrexone are $0.74 per
333-mg tablet (vs $0.64 baseline) and $4.29 per 50-mg tablet (vs
$1.37 baseline), respectively. We varied labor costs by using the
25th and 75th percentiles of site labor costs for performing MM
and CBI (vs the median baseline). We performed 1-way sensi-
tivity analyses in which we first varied pharmaceutical prices alone
(all else the same) and staff wages alone (all else the same as initial
values) and then performed 2-way sensitivity analyses in which
we varied both pharmaceutical prices and staff wages
simultaneously.
RESULTS
Table 1 gives the mean costs of each intervention sepa-
rated into the following categories: medications, labor
costs of MM and CBI, and costs of laboratory and non-
laboratory assessments. Nonlaboratory assessments in-
cluded a medical history, a physical examination, and
other assessments received by every patient and dis-
cussed in Zarkin et al.13 With the exception of medica-
tion costs, there are no significant differences in cost
within a column across the interventions.
Table 1. Cost of Treatments
Treatment
No. of
Patients
Mean Cost, $
Medicationa
Labora Assessmentsa
Total Cost
of TreatmentMM CBI Nonlaboratory Laboratory
MM-placebo 153 167.38 132.29 109.58 409.25
CBI only 157 338.26 109.44 104.89 552.59
MM-naltrexone 154 268.45 162.63 131.22 108.86 671.16
MM-acamprosate 152 346.14 163.14 131.28 107.19 747.85
MM-placebo-CBI 156 164.62 349.63 132.98 110.67 757.90
MM-naltrexone-acamprosate 148 604.93 159.28 131.01 107.83 1003.06
MM-naltrexone-CBI 155 287.22 163.88 342.46 132.89 110.08 1036.53
MM-acamprosate-CBI 151 388.08 162.72 331.85 132.85 110.37 1125.86
MM-naltrexone-acamprosate-CBI 157 601.07 154.25 318.06 131.32 108.25 1312.96
All Treatmentsb 1383 415.46 162.23 336.05 129.43 108.63 845.91
Abbreviations: CBI, combined behavioral intervention; MM, medical management.
aData do not sum to total cost of treatment due to rounding.
bThe mean costs of medication, labor for MM, and labor for CBI are conditional on treatment arms that provided the relevant service; therefore, the sum of
these means will not equal the mean total cost of treatment across all treatments.
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The results of the cost-effectiveness analysis for the 3
outcomes are given in Table 2. Mean (adjusted) cost
and effectiveness represent the results per patient in each
of the 9 arms of the COMBINE Study. The least expen-
sive intervention ($409 per patient) was MM-placebo, and
the most expensive ($1313 per patient) was MM-
naltrexone-acamprosate-CBI. For 2 of the 3 outcomes,
CBI-only demonstrated the smallest mean effectiveness,
and MM-naltrexone-acamprosate demonstrated the larg-
est mean effectiveness for all outcomes.
Mean costs and effectiveness are reported for each out-
come, followed by the results of the cost-effectiveness analy-
sis. For PDA and the proportion of patients avoiding heavy
drinking, CBI-only is strictly dominated from an eco-
nomic perspective by MM-placebo because MM-placebo
therapy is less expensive and more effective than CBI; for
the proportion of patients achieving a good clinical out-
come, CBI-only is weakly economically dominated. For all
outcomes, MM-placebo is not economically dominated (it
is the least expensive intervention) and is on the cost-
effectiveness frontier. Moving down the column from MM-
placebo to more expensive interventions, MM-naltrexone
is less expensive and more effective than all intervening in-
terventions except for MM-naltrexone-acamprosate; thus,
these intervening interventions are strictly economically
dominated.MovingdownthecolumnfromMM-naltrexone-
acamprosate, the remaining interventions are strictly eco-
nomically dominated because they are more expensive and
less effective than MM-naltrexone-acamprosate.
The cost-effectiveness results based on the means for
all 3 outcomes show that only 3 interventions are in-
cluded in the cost-effective choice set: MM-placebo, MM-
naltrexone, and MM-naltrexone-acamprosate (see the
boldface interventions in Table 2). The ICER moving from
MM-placebo to MM-naltrexone is $42 per percentage
point increase in PDA, $2847 per patient of avoiding heavy
drinking, and $1690 per patient of achieving a good clini-
cal outcome. The ICER moving from MM-naltrexone to
MM-naltrexone-acamprosate is at least 21⁄2 times greater
for all outcomes: $664 per percentage point increase in
PDA (more than 15 times greater), $8095 per patient of
avoiding heavy drinking, and $7543 per patient of achiev-
ing a good clinical outcome.
The Figure shows cost-effectiveness acceptability
curves, which show the probability that each of the in-
terventions is the most cost-effective for alternative val-
ues of WTP for the outcomes. The WTP represents al-
ternative dollar valuations that may be placed on each
outcome by decision makers, in this case, treatment pro-
viders. Because the WTP for each of these outcomes will
differ and no definitive values have been established for
them in the field, we present alternative WTP values. For
PDA (Figure, A), MM-placebo has the highest probabil-
ity of being the most cost-effective for low WTP values
($50); for moderate values of WTP ($50-$350), MM-
naltrexone has the highest probability of being the most
cost-effective, but that probability decreases as WTP in-
creases, and its probability converges to the probability
of MM-placebo-CBI. For high values of WTP,
MM-naltrexone-acamprosate has the highest probabil-
ity of being the most cost-effective; however, its prob-
ability never exceeds .40. The other 6 interventions have
small probabilities of being cost-effective.
For the other 2 outcomes (Figure, B and Figure, C),
MM-naltrexone has the highest probability of being the
most cost-effective for most of the low values of WTP
($8000); however, for WTP values greater than $8000,
MM-naltrexone-acamprosate has the largest probability
of being the most cost-effective (approximately .50). All
of the other interventions have relatively low probabili-
ties of being optimal (.20).
Table 2. Cost-effectiveness Analysisa
Treatment
Mean
Cost
Percent Days Abstinent
Proportion of Patients Who
Avoid Heavy Drinking
Proportion of Patients
With Good Clinical Outcomes
Mean
Effectiveness
ICER
(C/E, $)
Mean
Effectiveness
ICER
(C/E, $)
Mean
Effectiveness
ICER
(C/E, $)
MM-placebob 409.25 (6.49) 73.80 (2.32) 0.26 (0.03) 0.58 (0.04)
CBI only 552.59 (15.59) 66.70 (2.55) Economically
dominated
0.24 (0.04) Economically
dominated
0.61 (0.04) Economically
dominatedc
MM-naltrexone 671.16 (16.80) 80.00 (2.01) 42.24 0.35 (0.04) 2846.85 0.74 (0.04) 1689.74
MM-acamprosate 746.85 (19.37) 75.60 (2.20) Economically
dominated
0.33 (0.04) Economically
dominated
0.61 (0.04) Economically
dominated
MM-placebo-CBI 757.90 (16.90) 79.80 (2.03) Economically
dominated
0.31 (0.04) Economically
dominated
0.71 (0.04) Economically
dominated
MM-naltrexone-acamprosate 1003.06 (31.71) 80.50 (1.90) 663.80 0.39 (0.04) 8095.12 0.78 (0.04) 7543.18
MM-naltrexone-CBI 1036.53 (23.56) 75.90 (2.38) Economically
dominated
0.34 (0.04) Economically
dominated
0.75 (0.04) Economically
dominated
MM-acamprosate-CBI 1125.87 (28.78) 78.30 (2.05) Economically
dominated
0.35 (0.04) Economically
dominated
0.75 (0.04) Economically
dominated
MM-naltrexone-acamprosate-CBI 1312.96 (40.43) 77.60 (2.26) Economically
dominated
0.28 (0.04) Economically
dominated
0.74 (0.04) Economically
dominated
Abbreviations: CBI, combined behavioral intervention; C/E, change in cost over change in effectiveness; ICER, incremental cost-effectiveness ratio;
MM, medical management.
aMeans are predicted outcomes from COMBINE sample; standard errors from bootstrapped samples are in parentheses.
Ordered by ascending mean cost of treatment.
b Interventions in boldface are included in the cost-effective choice set based on mean values of cost and effectiveness.
cWeakly dominated by MM-naltrexone.
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Figure. Cost-effectiveness acceptability curves. A, Percentage of days abstinent (PDA). B, Cost-effectiveness acceptability curve: Proportion of patients who avoid
heavy drinking. C, Cost-effectiveness acceptability curve: Proportion of patients with good clinical outcomes. CBI indicates combined behavioral intervention;
MM medical management; and P, placebo.
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SENSITIVITY ANALYSIS
The cost-effectiveness results are sensitive to the price
of naltrexone; however, the results are not sensitive to
changes in wages. Under the high pharmaceutical price
scenario, naltrexone is approximately 3 times more ex-
pensive than the baseline case; acamprosate is approxi-
mately 15% more expensive. For all outcomes, MM-
naltrexone is no longer a cost-effective intervention at
the mean values. For PDA and the proportion of pa-
tients with good clinical outcomes, the cost-effective in-
terventions are now MM-placebo, MM-placebo-CBI, and
MM-naltrexone-acamprosate; for the proportion of pa-
tients not returning to heavy drinking, the cost-
effective interventions are now MM-placebo, MM-
acamprosate, and MM-naltrexone-acamprosate. The
ICERs associated with these interventions are similar in
magnitude to the baseline values but are uniformly larger
in the sensitivity analysis. The results of the 2-way sen-
sitivity analysis are the same as the 1-way analysis when
pharmaceutical prices are varied.
COMMENT
To our knowledge, ours is the first prospective cost and
cost-effectiveness study of combining pharmaceutical and
behavioral interventions for alcohol dependence. In ad-
dition, it is the first cost-effectiveness study for alcohol
dependence in the United States to be conducted along-
side a randomized, controlled, clinical trial (ie, COMBINE
Study). Only 1 previous prospective cost-effectiveness
analysis has been published, and it compared social be-
havior and network therapy to motivational enhance-
ment therapy in the United Kingdom.11
Our cost and cost-effectiveness analysis is from the per-
spective of the treatment provider in best clinical prac-
tice rather than from the perspective of the COMBINE
Study research protocol. This perspective enables policy
makers to apply the results in a real-world clinical set-
ting. Previous cost-effectiveness literature of pharma-
ceutical interventions for alcohol dependence is limited
and primarily represents the results of statistical mod-
els. No previous prospective studies exist of the cost and
cost-effectiveness of treatment for alcohol dependence
with naltrexone, and many acamprosate studies are based
on statistical models (eg, Poldrugo et al24 and Palmer et
al25) or represent the health care system perspective (eg,
Schädlich and Brecht26). Rychlik et al27 conducted a pro-
spective cohort study of the cost-effectiveness of acam-
prosate therapy.
The cost-effectiveness analysis based on the means of
cost and effectiveness yields 3 cost-effective options: MM-
placebo, MM-naltrexone, and MM-naltrexone-
acamprosate. Because MM-placebo is the least costly in-
tervention and MM-naltrexone-acamprosate has the
largest mean effectiveness for all 3 outcomes, these in-
terventions are included in the cost-effective choice set.
On the basis of mean effectiveness alone for PDA, MM-
naltrexone and MM-placebo-CBI are similar and might
be viewed as equivalent in a cost-effectiveness analysis;
however, MM-naltrexone is less costly, which makes it
more attractive on cost-effectiveness grounds. Clini-
cally, MM-placebo may not be a feasible treatment op-
tion because physicians do not prescribe placebos; thus,
MM-naltrexone and MM-naltrexone-acamprosate are the
2 viable cost-effective options for all 3 outcomes.
The statistical tests in Anton et al10 were the clinical
study’s prespecified tests of main effects and interac-
tions. These did not find a clinical benefit for acampro-
sate therapy either as a main effect or in 2- or 3-way
interactions; pairwise comparisons between MM-
naltrexone and MM-naltrexone-acamprosate were not pri-
mary or secondary hypotheses. In contrast, the prespeci-
fied comparisons for the cost-effectiveness analyses
involved investigating each treatment intervention rela-
tive to every other intervention in terms of the joint dis-
tribution of costs and effectiveness. Further, the pair-
wise comparisons presented herein are not formal
statistical tests of efficacy; on efficacy alone, MM-
naltrexone-acamprosate is not significantly better than
MM-naltrexone.10 However, on the basis of the joint dis-
tribution of cost and effectiveness, MM-naltrexone-
acamprosate may be a cost-effective choice that is se-
lected by decision makers under certain circumstances.
The choice of MM-naltrexone-acamprosate over MM-
naltrexone depends on whether the cost of the incre-
mental increase in mean effectiveness is justifiable by the
decision maker. For PDA, MM-naltrexone-acamprosate
has only a slightly larger mean effectiveness than MM-
naltrexone (0.5 PDA) but has an approximately 50% larger
mean cost per patient. This translates into an ICER for
an additional percentage point increase in PDA of $664,
which is an order of magnitude greater than switching
from MM-placebo to MM-naltrexone. If decision mak-
ers place a value on increases in PDA equal to or greater
than $664, they would be willing to pay the incremental
cost for MM-naltrexone-acamprosate; otherwise, they will
choose MM-naltrexone.
For the proportion of patients who avoid heavy drink-
ingandtheproportionofpatientswhoachieveagoodclini-
cal outcome, the ICER for MM-naltrexone-acamprosate
relative to MM-naltrexone is approximately 3 to 4 times
larger (approximately $7500 to $8000 per patient) com-
paredwithswitchingfromMM-placebotoMM-naltrexone.
If decision makers value increases in mean effectiveness
more than the incremental costs of achieving them, they
will choose the interventions with the greater mean cost
and effectiveness.
The cost-effectiveness acceptability curve analysis
shows that for all 3 outcomes, the probabilities that any
of the interventions are the most cost-effective are rela-
tively small except at the very lowest WTP values. Be-
yond a WTP of $350 per percentage point increase in PDA,
MM-naltrexone-acamprosate has the largest probability
of being the most cost-effective intervention, although
with a relatively small probability of between .30 and .40.
For decision makers with a relatively high dollar value
for PDA who choose MM-naltrexone-acamprosate be-
cause it has the highest probability of being cost-
effective, this choice will not be the most cost-effective
choice 60% to 70% of the time. Similarly, for the pro-
portion of patients who avoid heavy drinking and the pro-
portion of patients who achieve a good clinical out-
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come, the probability of MM-naltrexone-acamprosate
being the most cost-effective for large values of WTP is
also relatively small, in the range of .50 to .60.
The low probabilities of being cost-effective even at
high values of WTP are caused by 2 key factors: the
large number of treatment alternatives (9 vs the usual
2 or 3 alternatives in most cost-effective analysis stud-
ies), which lowers the probability of choosing any one
alternative, all else being equal; and the similarity of
many of the mean effectiveness estimates, which
makes it difficult to differentiate between the various
interventions.
The results are sensitive to the price of naltrexone,
which is expected because the sensitivity analysis as-
sumed the sticker prices for naltrexone and acampro-
sate, which increases the naltrexone price by more than
200% (or 3-fold) but only increases the price of acam-
prosate by 15%. We believe that most providers, and al-
most certainly large providers, will have access to nal-
trexone at the discounted baseline values; however, to
the extent that they do not, our sensitivity results may
provide a more accurate perspective of the cost-
effectiveness of the COMBINE Study intervention.
Our study has 3 primary limitations. First, our cost
analysis relies on the judgment of the cost-effectiveness
study principal investigators as to which activities are
primarily research-related and which would be used in
best clinical practice.13 To minimize this issue, we
implemented a consensus approach to achieve agree-
ment on best clinical practice activities. Each interven-
tion arm except CBI incurs almost the exact same cost
for these activities; therefore, any errors in this task will
have no differential effect across the arms and will not
affect the cost-effectiveness analysis. Second, although
we have attempted to identify activities that would be
part of best clinical practice from the perspective of the
treatment provider, the treatment regimen we use in
our costing algorithm follows the COMBINE Study pro-
tocol. We expect that patients are seen more frequently
in a clinical trial compared with best clinical practice;
thus, we expect our cost estimates to be the upper lim-
its of the actual best practice treatment costs. Future
work may examine the cost and cost-effectiveness from
other perspectives such as the third-party payer or the
patient. Third, our cost-effectiveness results depend on
the interventions that were included in the COMBINE
Study. An alternative set of interventions provides dif-
ferent comparisons between cost and effectiveness, and
different cost-effectiveness results. Furthermore, the
cost-effectiveness results may differ if alternative clini-
cal and economic end points are used (eg, quality of life
and overall functioning).
Despite these limitations, our cost study provides an im-
portant analysis of the cost and cost-effectiveness of the
COMBINE Study therapies. As is typical in cost-
effectiveness studies, the choice of the optimal (ie, most
cost-effective) intervention depends on the value placed on
the outcomes by the ultimate decision maker. Further-
more, decision makers may have different preferences for
the 3 outcomes, and their choice of the optimal interven-
tion may differ by clinical outcome. The similarity of many
of the mean effectiveness estimates suggests that future work
that explores moderators of treatment outcome has the po-
tential to improve the understanding of both treatment out-
come and its cost-effectiveness.
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